Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more
Market Cap & Net Worth: Immutep Limited (PRRUF)
Immutep Limited (PINK:PRRUF) has a market capitalization of $294.38 Million ($294.38 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #13946 globally and #5691 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immutep Limited's stock price $0.20 by its total outstanding shares 1471920338 (1.47 Billion).
Immutep Limited Market Cap History: 2015 to 2025
Immutep Limited's market capitalization history from 2015 to 2025. Data shows change from $482.79 Million to $294.38 Million (-5.18% CAGR).
Immutep Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immutep Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
58.37x
Immutep Limited's market cap is 58.37 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $219.32 Million | $175.05K | -$62.02 Million | 1252.86x | N/A |
| 2017 | $175.16 Million | $4.12 Million | -$9.37 Million | 42.55x | N/A |
| 2018 | $145.72 Million | $2.63 Million | -$12.75 Million | 55.40x | N/A |
| 2019 | $213.43 Million | $139.78K | -$18.34 Million | 1526.87x | N/A |
| 2020 | $529.89 Million | $7.49 Million | -$13.47 Million | 70.78x | N/A |
| 2021 | $485.73 Million | $119.95K | -$29.90 Million | 4049.43x | N/A |
| 2022 | $279.66 Million | $170.37K | -$32.21 Million | 1641.52x | N/A |
| 2023 | $353.26 Million | $3.51 Million | -$39.90 Million | 100.77x | N/A |
| 2024 | $294.38 Million | $3.84 Million | -$42.72 Million | 76.63x | N/A |
| 2025 | $294.38 Million | $5.04 Million | -$61.43 Million | 58.37x | N/A |
Competitor Companies of PRRUF by Market Capitalization
Companies near Immutep Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Immutep Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Immutep Limited Historical Marketcap From 2015 to 2025
Between 2015 and today, Immutep Limited's market cap moved from $482.79 Million to $ 294.38 Million, with a yearly change of -5.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $294.38 Million | 0.00% |
| 2024 | $294.38 Million | -16.67% |
| 2023 | $353.26 Million | +26.32% |
| 2022 | $279.66 Million | -42.42% |
| 2021 | $485.73 Million | -8.33% |
| 2020 | $529.89 Million | +148.28% |
| 2019 | $213.43 Million | +46.46% |
| 2018 | $145.72 Million | -16.81% |
| 2017 | $175.16 Million | -20.13% |
| 2016 | $219.32 Million | -54.57% |
| 2015 | $482.79 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Immutep Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $294.38 Million USD |
| MoneyControl | $294.38 Million USD |
| MarketWatch | $294.38 Million USD |
| marketcap.company | $294.38 Million USD |
| Reuters | $294.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.